X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (247) 247
Publication (80) 80
Patent (19) 19
Dissertation (3) 3
Book Chapter (2) 2
Compact Disc (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (90) 90
oncology (79) 79
index medicus (74) 74
female (72) 72
male (70) 70
middle aged (67) 67
adult (64) 64
aged (55) 55
brain neoplasms - drug therapy (45) 45
malignant glioma (39) 39
bevacizumab (36) 36
clinical neurology (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
glioblastoma (34) 34
temozolomide (34) 34
abstracts (33) 33
dacarbazine - analogs & derivatives (29) 29
gliomas (29) 29
article (28) 28
glioblastoma multiforme (28) 28
treatment outcome (28) 28
chemotherapy (27) 27
glioblastoma - drug therapy (27) 27
cancer (25) 25
glioma - drug therapy (25) 25
glioma (24) 24
brain neoplasms - mortality (23) 23
brain neoplasms - pathology (23) 23
brain tumors (22) 22
neoplasm recurrence, local - drug therapy (22) 22
medicine & public health (21) 21
neurology (20) 20
dacarbazine - administration & dosage (19) 19
human necessities (19) 19
hygiene (19) 19
medical or veterinary science (19) 19
preparations for medical, dental, or toilet purposes (19) 19
angiogenesis (18) 18
brain neoplasms - therapy (18) 18
care and treatment (18) 18
beer (17) 17
biochemistry (17) 17
chemistry (17) 17
clinical trials (17) 17
compositions thereof (17) 17
culture media (17) 17
enzymology (17) 17
metallurgy (17) 17
microbiology (17) 17
microorganisms or enzymes (17) 17
mutation or genetic engineering (17) 17
propagating, preserving or maintaining microorganisms (17) 17
radiation therapy (17) 17
spirits (17) 17
vascular endothelial growth factor (17) 17
vinegar (17) 17
wine (17) 17
endothelial growth-factor (16) 16
phase-ii trial (16) 16
radiotherapy (16) 16
tumors (16) 16
angiogenesis inhibitors - therapeutic use (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
camptothecin - analogs & derivatives (15) 15
disease-free survival (15) 15
survival rate (15) 15
young adult (15) 15
general tagging of cross-sectional technologies spanning over several sections of the ipc (14) 14
general tagging of new technological developments (14) 14
glioma - pathology (14) 14
survival (14) 14
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (14) 14
technologies for adaptation to climate change (14) 14
technologies or applications for mitigation or adaptation againstclimate change (14) 14
dacarbazine - adverse effects (13) 13
glioblastoma - therapy (13) 13
glioblastoma-multiforme (13) 13
glioma - mortality (13) 13
irinotecan (13) 13
specific therapeutic activity of chemical compounds ormedicinal preparations (13) 13
toxicity (13) 13
camptothecin - administration & dosage (12) 12
electrotherapy (12) 12
glioblastoma - pathology (12) 12
magnetotherapy (12) 12
maximum tolerated dose (12) 12
survival analysis (12) 12
ultrasound therapy (12) 12
abridged index medicus (11) 11
angiogenesis inhibitors (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
combined modality therapy (11) 11
follow-up studies (11) 11
malignant gliomas (11) 11
neoplasm recurrence, local - mortality (11) 11
prognosis (11) 11
research (11) 11
adults (10) 10
antibodies, monoclonal - administration & dosage (10) 10
antineoplastic agents - therapeutic use (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE REVIEWS NEUROLOGY, ISSN 1759-4758, 08/2015, Volume 11, Issue 8, pp. 429 - 429
Bevacizumab is approved for use in recurrent glioblastoma, but whether it benefits patients with newly diagnosed glioblastoma remains unclear. Two new studies... 
PHASE-II TRIAL | NEWLY-DIAGNOSED GLIOBLASTOMA | VEGF | CLINICAL NEUROLOGY | TEMOZOLOMIDE | Drug therapy | Glioblastoma multiforme
Journal Article
Perspectives interdisciplinaires sur le travail et la santé, 02/2010
L’obligation d’accommodement des salariés handicapés, à la faveur de développements jurisprudentiels importants, a pris une certaine ampleur au Québec, de... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 150 - 161
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7543, pp. 366 - 369
After stimulation, dendritic cells(DCs) mature andmigrate to draining lymph nodes to induce immune responses(1). As such, autologous DCs generated ex vivo have... 
MALIGNANT GLIOMA | RESPONSES | IMMUNITY | MULTIDISCIPLINARY SCIENCES | HUMAN CYTOMEGALOVIRUS | VACCINATION | PERIPHERAL-BLOOD | MELANOMA-CELLS | MIP-1-ALPHA | TUMORS | T-CELLS | Phosphoproteins - immunology | Immunotherapy - methods | Viral Matrix Proteins - genetics | Chemokine CCL3 - immunology | Dendritic Cells - immunology | Humans | Substrate Specificity | Phosphoproteins - chemistry | CD4-Positive T-Lymphocytes - immunology | Cancer Vaccines - therapeutic use | Dendritic Cells - drug effects | Female | Lymph Nodes - drug effects | Tetanus Toxoid - pharmacology | Antigens, Neoplasm - immunology | Cancer Vaccines - administration & dosage | Mice, Inbred C57BL | Tetanus Toxoid - therapeutic use | Survival Rate | Treatment Outcome | Lymph Nodes - immunology | Phosphoproteins - genetics | Lymph Nodes - cytology | Tetanus Toxoid - administration & dosage | Glioblastoma - therapy | Cancer Vaccines - immunology | Cell Movement - drug effects | Animals | Glioblastoma - immunology | Viral Matrix Proteins - chemistry | Glioblastoma - pathology | Dendritic Cells - cytology | Mice | Viral Matrix Proteins - immunology | Glioblastoma - drug therapy | CD4-Positive T-Lymphocytes - drug effects | Medical research | Dendritic cells | Physiological aspects | Medicine, Experimental | Vaccines | Research | Glioblastoma multiforme | Immunization | Lymphocytes | Medical prognosis | Clinical trials | Tetanus | Chemokines
Journal Article
Journal Article
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 5, pp. 2018 - 2024
Purpose Patients with recurrent malignant gliomas treated with stereotactic radiosurgery (SRS) and multiagent systemic therapies were reviewed to determine the... 
Radiology | Hematology, Oncology and Palliative Medicine | Stereotactic radiosurgery | Vascular endothelial growth factor-A | Glioma | Bevacizumab | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | ANGIOGENESIS | GLIOBLASTOMA-MULTIFORME | REIRRADIATION | VEGF | REOPERATION | RADIATION | TUMORS | ONCOLOGY | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Multivariate Analysis | Follow-Up Studies | Dacarbazine - therapeutic use | Humans | Middle Aged | Brain Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Neoplasm Recurrence, Local - mortality | Radiosurgery - adverse effects | Neoplasm Recurrence, Local - pathology | Young Adult | Glioma - pathology | Treatment Failure | Dacarbazine - analogs & derivatives | Glioma - therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Retrospective Studies | Brain Neoplasms - mortality | Radiosurgery - methods | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Glioma - mortality | Neoplasm Recurrence, Local - therapy | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Brain Neoplasms - therapy | Aged | Combined Modality Therapy - methods | Salvage Therapy - methods | Antimitotic agents | Care and treatment | Gliomas | Nuclear radiation | Surgery | Radiosurgery | Angiogenesis inhibitors | Radiotherapy | Antineoplastic agents | temozolomide | Toxicity | Brain tumors | Risk assessment | Adjuvants | Multivariate analysis | Survival | Age | Index Medicus | GLIOMAS | SURGERY | DIAGNOSIS | GROWTH FACTORS | MULTIVARIATE ANALYSIS | PATIENTS | RADIOLOGY AND NUCLEAR MEDICINE | DEATH | TOXICITY | HAZARDS
Journal Article
Journal Article
Nature Reviews Neurology, ISSN 1759-4758, 05/2012, Volume 8, Issue 5, pp. 244 - 246
A new standard of care for glioblastoma, an infrequent and invariably fatal neoplasm, was readily accepted by the neuro-oncology community in 2005 after the... 
Glioblastoma - therapy | Standard of Care - standards | Social Welfare | Glioblastoma - diagnosis | United States | Brain Neoplasms - diagnosis | Humans | Brain Neoplasms - therapy | Glioblastoma - epidemiology | Brain Neoplasms - epidemiology
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 3/2012, Volume 107, Issue 1, pp. 155 - 164
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 1/2010, Volume 96, Issue 2, pp. 219 - 230
Journal Article